Toggle menu

Emily Godden

Senior Research Nurse - Renal/Acute Medicine

Emily Godden

When I got offered a job as a newly qualified staff nurse working in the renal department I was delighted but terrified. I quickly buried my head into a textbook in an attempt to refresh my memory about how this complex organ works and memorise all of the normal blood values ready for my first day!

 

It has never been a dull day working as a renal nurse. The patient group I care for ensures this. Their charisma and resilience humbles me and each individual I have cared for has taught me different lessons.

 

I was also very lucky to work with such an excellent and very knowledgeable team, all of whom always had the patient at the very heart of their work. It was fascinating to hear about the research some of the renal doctors were carrying out to help improve care and outcomes for this patient group. When the opportunity arose to participate in this research I jumped at this chance.

 

Joining a team of researchers dedicated to improving healthcare has been an amazing experience, It has been inspiring to see how the EMERGE team has pioneered healthcare within the emergency department. For me, it is a very exciting prospect that the EMERGE team have expanded to include renal research. With their support and expertise I hope to help develop and expand research in this area whilst making it more visible and ultimately helping to make a difference in the care and disease trajectory of these patients.


Trials

KRAKIL Study

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study